Department of Critical Care Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Cancer Med. 2023 Aug;12(15):16243-16253. doi: 10.1002/cam4.6288. Epub 2023 Jul 17.
Over the past decade, ECMO has provided temporary cardiopulmonary support to an increasing number of patients, but the use of extracorporeal membrane oxygenation (ECMO) to provide temporary respiratory and circulatory support to adult patients with malignancy remains controversial.
This paper reviews the specific use of extracorporeal membrane oxygenation (ECMO) in oncology patients.
We searched PubMed, CINAHL, Cochrane Library, and Embase databases for studies on the use of ECMO in cancer patients between 1998 and 2022. Twenty-four retrospective, prospective, and case reports were included. The primary outcome was survival during extracorporeal membrane oxygenation.
Most studies suggest that ECMO can be used in oncology patients requiring life support during surgery, solid tumor patients with respiratory failure, and hematological tumor patients requiring ECOM as a supportive means of chemotherapy; however, in patients with hematologic oncology undergoing hematopoietic stem cell transplantation, there was no clear benefit after the use of ECMO.
Current research suggests that ECMO may be considered as a salvage support in specific cancer patients. Future studies should include larger sample sizes than those already conducted, including studies on efficacy, adverse events, and health.
在过去的十年中，ECMO 为越来越多的患者提供了临时心肺支持，但在恶性肿瘤成年患者中使用体外膜氧合（ECMO）来提供临时呼吸和循环支持仍存在争议。
本文回顾了 ECMO 在肿瘤患者中的具体应用。
我们检索了 1998 年至 2022 年间在 PubMed、CINAHL、Cochrane 图书馆和 Embase 数据库中关于 ECMO 在癌症患者中应用的研究。纳入了 24 篇回顾性、前瞻性和病例报告。主要结局是 ECMO 期间的生存情况。
大多数研究表明，ECMO 可用于需要手术期间生命支持的肿瘤患者、患有呼吸衰竭的实体瘤患者以及需要 ECOM 作为化疗支持手段的血液系统肿瘤患者；然而，在接受造血干细胞移植的血液系统恶性肿瘤患者中，使用 ECMO 后并没有明显获益。
目前的研究表明，ECMO 可以被认为是特定癌症患者的挽救性支持手段。未来的研究应包括比以往研究更大的样本量，包括对疗效、不良事件和健康状况的研究。
